| Dr Richard Thomas, MD | |
|
Lahey Hospital & Medical Center, 41 Mall Road, Burlington, MA 01805 | |
| (781) 744-8170 | |
| (781) 744-5232 |
| Full Name | Dr Richard Thomas |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 15 Years |
| Location | Lahey Hospital & Medical Center, Burlington, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043763758 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 266786 (Massachusetts) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 280897 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lahey Hospital & Medical Center, Burlington | Burlington, MA | Hospital |
| Beth Israel Deaconess Medical Center | Boston, MA | Hospital |
| Winchester Hospital | Winchester, MA | Hospital |
| Northeast Hospital Corporation | Beverly, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lahey Clinic Inc | 2264336528 | 1211 |
News Archive
Scientists have developed a new drug which can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.
The U.S. Food and Drug Administration has approved the first transplant of fetal stem cells into human brains, a procedure that if successful could pave the way to treating a host of neural disorders.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.
Joint venture partners Rainbow Coral Corp. and Nano3D Biosciences (n3D) are proud to announce that the journal Scientific Reports published the first research document detailing the efficacy of n3D's revolutionary new Apple iPhone app today.
A new partnership between the Indiana University and Kenya's Moi University will develop master's degrees at both universities that focus on ethical issues in international health research.
› Verified 8 days ago
| Entity Name | Lahey Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538194980 PECOS PAC ID: 2264336528 Enrollment ID: O20031120000097 |
News Archive
Scientists have developed a new drug which can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.
The U.S. Food and Drug Administration has approved the first transplant of fetal stem cells into human brains, a procedure that if successful could pave the way to treating a host of neural disorders.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.
Joint venture partners Rainbow Coral Corp. and Nano3D Biosciences (n3D) are proud to announce that the journal Scientific Reports published the first research document detailing the efficacy of n3D's revolutionary new Apple iPhone app today.
A new partnership between the Indiana University and Kenya's Moi University will develop master's degrees at both universities that focus on ethical issues in international health research.
› Verified 8 days ago
| Entity Name | Lahey Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063447316 PECOS PAC ID: 2264336528 Enrollment ID: O20040629001269 |
News Archive
Scientists have developed a new drug which can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.
The U.S. Food and Drug Administration has approved the first transplant of fetal stem cells into human brains, a procedure that if successful could pave the way to treating a host of neural disorders.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.
Joint venture partners Rainbow Coral Corp. and Nano3D Biosciences (n3D) are proud to announce that the journal Scientific Reports published the first research document detailing the efficacy of n3D's revolutionary new Apple iPhone app today.
A new partnership between the Indiana University and Kenya's Moi University will develop master's degrees at both universities that focus on ethical issues in international health research.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard Thomas, MD Lahey Hospital & Medical Center, 41 Mall Road, Burlington, MA 01805-0001 Ph: (781) 744-8170 | Dr Richard Thomas, MD Lahey Hospital & Medical Center, 41 Mall Road, Burlington, MA 01805 Ph: (781) 744-8170 |
News Archive
Scientists have developed a new drug which can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.
The U.S. Food and Drug Administration has approved the first transplant of fetal stem cells into human brains, a procedure that if successful could pave the way to treating a host of neural disorders.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.
Joint venture partners Rainbow Coral Corp. and Nano3D Biosciences (n3D) are proud to announce that the journal Scientific Reports published the first research document detailing the efficacy of n3D's revolutionary new Apple iPhone app today.
A new partnership between the Indiana University and Kenya's Moi University will develop master's degrees at both universities that focus on ethical issues in international health research.
› Verified 8 days ago
David A Rosman, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Lahey Clinic, 41 Mall Road, Burlington, MA 01805 Phone: 781-744-8170 | |
Dr. Jonathan Rassi, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 41 Mall Road, Lahey Hospital & Medical Center, Burlington, MA 01805 Phone: 781-744-8170 Fax: 781-744-5232 | |
Patricia M. Morris, M.D. Radiology Medicare: Medicare Enrolled Practice Location: Lahey Clinic, 41 Mall Road, Burlington, MA 01805 Phone: 781-744-5100 Fax: 781-744-5215 | |
Laura Cadogan, Radiology Medicare: Accepting Medicare Assignments Practice Location: 41 Mall Rd, Burlington, MA 01805 Phone: 781-744-5114 | |
Reza Hakimelahi, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 41 Mall Rd, Burlington, MA 01805 Phone: 781-744-8000 Fax: 781-744-3707 | |
Dr. Grace M. Lee, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Lahey Clinic, 41 Mall Road, Burlington, MA 01805 Phone: 781-744-8170 Fax: 781-744-5232 |